Shortly after the onset of clinical T1D and the initiation of insulin therapy, about two-thirds of the individuals with T1D exhibit a transient and partial spontaneous clinical remission phase (also referred to as the “honeymoon phase”), which is accompanied by a substantial reduction in exogenous insulin requirements and near-normal glucose control (6–9). This evidence concerns the gene INS and type 1 diabetes mellitus.